Shire launches DosEdge in India

The new hemophilia factor-dosage calculation mobile app for healthcare professionals, available free on Apple App Store and Google Play Store, ensures dosage accuracy for patients with hemophilia


New Delhi: Shire India, a leading global biotechnology company focused on serving people with rare diseases, on 6th December announced the availability of DosEdge. The new free mobile app aids healthcare professionals in determining the appropriate dosage of antihemophilic factor/drug. Currently, healthcare professionals manually calculate factor dosage and frequency use variables like severity level, bleeding spot, patient’s body weight, and the treatment type – prophylactic or on-demand. Missing any of the parameters may lead to sub-optimal treatment.

DosEdge safeguards dosage accuracy and reduces the incidence of error, thereby helping physicians develop personalized dosing regimens tailored to specific needs of their respective patients. The app is available to healthcare professionals through the Apple App Store and Google Play Store. The app is free, does not require an active internet connection, has a simple user interface and needs minimal data inputs. However, the app uses data analysis to make accurate and critical dosage calculations for factor replacement. With just a few clicks, the app enables healthcare professionals to assess their patients’ accurate factor dosage requirement and helping them retain full control over their prescription practice.

“As part of our commitment to meeting the unmet needs of hemophilia patients, we are pleased to introduce DosEdge, an innovative mobile app for healthcare professionals in India.” said Vineet Singhal, Country Head, Shire India.

Hemophilia is a lifelong bleeding disorder in which patients do not have enough clotting factor, a naturally occurring protein in blood that controls bleeding. People with Hemophilia do not bleed more profusely or faster than normal, but bleed for a longer period of time. The disease primarily affects males, and with about 1 in 5,000 people being born with the condition. Alugh there is no cure, patients with Hemophilia typically receive a treatment called “factor replacement therapy” to help their blood clot (the body’s normal process to stop bleeding).